Technology
How we make the impossible possible.
Our pioneering technology unlocks the potential to identify and develop small molecule modulators of previously undruggable disordered proteins.
The uncharted territory of disordered proteins has long been overlooked
Due to the complexity of targeting intrinsically disordered regions (IDRs) with conventional approaches, the key to unlocking these targets lies in the understanding of their native dynamic structural behaviour.
Technology
Unlocking Transiently Druggable States for Small Molecule Discovery
At Nuage, we have developed a dedicated suite of technologies that zoom in on the transiently druggable states enabling the discovery and development of small molecule modulators.
Target Discovery Algorithm (TDA)
Our proprietary target prioritization tool is an IDR knowledge vault designed to systematically identify, evaluate, and prioritize previously undruggable targets with the highest potential for therapeutic intervention.
Reconstitution of IDRs into druggable conformations
Our approach harnesses the natural behaviour of IDRs to induce binding-enabled transient structural ordering, thereby unlocking the translatability of small molecule discovery to the native biological setting of IDRs.
C-Assay and Suite of Biophysical Assays
Our proprietary biophysics toolbox leverages the unique know-how of IDR conformational states and enables high-throughput screening and deep characterisation of selective covalent small molecule binding events.
Unprecedented Inhibition Mechanism
Sustained covalent binding to the disordered regions results in persistent inhibition of aberrant functions and provides groundbreaking opportunities for precision cancer treatment.
Sustained inhibition
Blocks essential protein-protein interactions
Destabilises structure to inhibit function
Target Discovery Algorithm (TDA)
Our proprietary target prioritization tool is an IDR knowledge vault designed to systematically identify, evaluate, and prioritize previously undruggable targets with the highest potential for therapeutic intervention.
Learn More
Close
Reconstitution of IDRs into druggable conformations
Our approach harnesses the natural behaviour of IDRs to induce binding-enabled transient structural ordering, thereby unlocking the translatability of small molecule discovery to the native biological setting of IDRs.
Learn More
Close
C-Assay and Suite of Biophysical Assays
Our proprietary biophysics toolbox leverages the unique know-how of IDR conformational states and enables high-throughput screening and deep characterisation of selective covalent small molecule binding events.
Learn More
Close
Unprecedented Inhibition Mechanism
Sustained covalent binding to the disordered regions results in persistent inhibition of aberrant functions and provides groundbreaking opportunities for precision cancer treatment.
Learn More
Close
Sustained inhibition
Blocks essential protein-protein interactions
Destabilises structure to inhibit function
We are unlocking a critical target class for efficient drug discovery
Through our technologies, we successfully identified functional inhibitors of multiple high-value oncogenic transcription factors, unlocking this critical target class for efficient drug discovery.